Turnaround delayed but hope remains intact
20/03/23 -"Our positive recommendation on UCB is reiterated, backed by the strong growth potential of its newer crop of drugs and late-stage pipeline, and eventual profitability/cashflow improvements (even ..."
Pages
58
Language
English
Published on
20/03/23
You may also be interested by these reports :
12/05/25
Lonza’s management expressed confidence in meeting the FY guidance. Capex projects are progressing as planned, contributing positively to ...
10/05/25
Genmab reported mixed Q1 results. Strong sales growth, driven by key offerings, resulted in solid profitability. Although our model is under review, ...
09/05/25
Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of ...
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...